E. Ruth Plummer
Impact in
-
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Papers in
- Oncology 10
- Cancer Treatment and Pharmacology 4
- PARP inhibition in cancer therapy 3
-
- Cancer therapeutics and mechanisms 3
- Co-authors
- A H Calvert (6 shared papers)Alan V. Boddy (4 shared papers)Nicola J. Curtin (4 shared papers)Melanie Griffin (2 shared papers)Branimir I. Šikić (2 shared papers)Julieann Sludden (1 shared paper)Suzanne F. Jones (2 shared papers)L Robson (2 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)Molecular Cancer Therapeutics (3 papers)Clinical Cancer Research (3 papers)British Journal of Cancer (3 papers)Investigational New Drugs (1 paper)
- Partner nations
- United KingdomUnited StatesCanada
In The Last Decade
E. Ruth Plummer
20 papers receiving 463 citations
Peers
Comparison fields: 5 of 66
- Oncology 210
- Cancer Research 94
- Genetics 57
- Biomaterials 64
- Reproductive Medicine 38
Countries citing papers authored by E. Ruth Plummer
This map shows the geographic impact of E. Ruth Plummer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Ruth Plummer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Ruth Plummer more than expected).
Fields of papers citing papers by E. Ruth Plummer
This network shows the impact of papers produced by E. Ruth Plummer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Ruth Plummer. The network helps show where E. Ruth Plummer may publish in the future.
Co-authors
The 25 scholars most cited alongside E. Ruth Plummer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 84 | |
| 2 | 2009 | 77 | |
| 3 | 2011 | 45 | |
| 4 | 2007 | 42 | |
| 5 | 2015 | 37 | |
| 6 | A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. | 2007 | 33 |
| 7 | 2010 | 25 | |
| 8 | 2014 | 21 | |
| 9 | 2005 | 19 | |
| 10 | 2009 | 19 | |
| 11 | 2008 | 13 | |
| 12 | 2006 | 13 | |
| 13 | 2000 | 12 | |
| 14 | 2021 | 10 | |
| 15 | A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors | 1999 | 7 |
| 16 | Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide | 2005 | 6 |
| 17 | 2009 | 3 | |
| 18 | Poly(ADP-ribose) polymerase-1 (PARP-1) genomics in relation to activity in healthy volunteers and cancer patients | 2008 | 2 |
| 19 | 2023 | 1 | |
| 20 | 2010 | 1 |
About E. Ruth Plummer
E. Ruth Plummer is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Cell Biology, having authored 20 papers that have together received 470 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), Microtubule and mitosis dynamics (4 papers), Cancer therapeutics and mechanisms (3 papers), PARP inhibition in cancer therapy (3 papers), Cancer Genomics and Diagnostics (3 papers), Cancer Research and Treatments (2 papers), Nanoparticle-Based Drug Delivery (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Oncology (210 citations), Cancer Research (94 citations), Genetics (57 citations), Biomaterials (64 citations) and Reproductive Medicine (38 citations). E. Ruth Plummer has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include A H Calvert, Alan V. Boddy, Nicola J. Curtin, Melanie Griffin, Branimir I. Šikić, Julieann Sludden, Suzanne F. Jones, L Robson, Nancy Lewis and James T. Cassidy. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, British Journal of Cancer and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.